Search Results

You are looking at 71 - 80 of 107 items for :

  • "microsatellite instability" x
Clear All
Full access

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, Carlos Corvera, Prajnan Das, Crystal S. Denlinger, Peter C. Enzinger, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael Gibson, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kimberly L. Johung, Rajesh N. Keswani, Lawrence R. Kleinberg, Stephen Leong, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Ravi K. Paluri, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Robert Roses, Vivian E. Strong, Georgia Wiesner, Christopher G. Willett, Cameron D. Wright, Nicole R. McMillian and Lenora A. Pluchino

in accordance with guidelines for gastric cancer. Principles of Biomarker Testing Presently, molecular testing for HER2 status, microsatellite instability status, and programmed death-ligand 1 (PD-L1) expression are used in the clinical management of

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory and Deborah A. Freedman-Cass

(notably chemotherapy-induced peripheral neuropathy), 16 , 20 and not all patients derive benefit. Consideration of disease stage and pathologic features, microsatellite instability (MSI) status, possible efficacy and toxicity profiles associated with

Full access

Swaminathan Murugappan, William P. Harris, Christopher G. Willett and Edward Lin

role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer . Int J Colorectal Dis 2007 ; 22 : 739 – 748 . 10. Nilbert M Planck M Fernebro E . Microsatellite instability is rare in rectal carcinomas and signifies hereditary

Full access

Bishal Gyawali, Elvira D’Andrea, Jessica M. Franklin and Aaron S. Kesselheim

planned to do the same in case we encountered such an occurrence. With regard to immunotherapies, we included microsatellite instability (MSI)– or mismatch repair (MMR)–based approvals as biomarker-based approvals, but excluded PD-L1–based approvals. MSI

Full access

Alexander S. Baras, Jarushka Naidoo, Christine L. Hann, Peter B. Illei, Charles W. Reninger III and Josh Lauring

burden was not calculated, also presumably because of inadequate sample quality or DNA quantity. The MLH1 R325Q mutation has been reported previously in the germline in a few Lynch syndrome families, but it has not been associated with microsatellite

Full access

Maxwell T. Vergo and Al B. Benson III

adjuvant chemotherapy. Emerging Tools and Biomarkers Microsatellite instability high (MSI-H) has emerged as a new biomarker, with both prognostic and predictive implications for adjuvant therapy. Sargent et al 18 reported a 5-year DFS of 75% for

Full access

Victor T.G. Lin, Lisle M. Nabell, Sharon A. Spencer, William R. Carroll, Shuko Harada and Eddy S. Yang

. Thyroid 2017 ; 27 : 1201 – 1205 . 24. Moschetta M Mak G Hauser J . Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer . Exp Hematol Oncol 2017

Full access

Nikolaos A. Trikalinos, Amy Zhou, Maria B. Majella Doyle, Kathryn J. Fowler, Ashley Morton, Neeta Vachharajani, Manik Amin, Jesse W. Keller, William C. Chapman, Elizabeth M. Brunt and Benjamin R. Tan

, and others. Immunotherapy can be used for microsatellite instability-high (MSI-H) patients. With the approval of second-line nivolumab in HCC, use of checkpoint inhibitors for this rare biphenotypic tumor needs to be further studied. In our cohort of

Full access

Katy K. Tsai, Neharika Khurana, Timothy McCalmont, Adil Daud, Boris Bastian and Iwei Yeh

(dMMR) and can result in microsatellite instability (MSI) in a variety of solid tumors. Given the known role of PTCH1 gene mutation and the Shh signaling pathway in BCC pathogenesis, the patient was diagnosed with clear cell BCC and was started on

Full access

James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael R. Kuettel, Joshua M. Lang, Jesse McKenney, George Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A. Shead and Deborah A. Freedman-Cass

, for treatment of patients with “unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair (MMR)-deficient solid tumors who have progressed on prior treatment and who have no satisfactory alternative treatment options” on May